XML 45 R31.htm IDEA: XBRL DOCUMENT v3.22.4

Revenues (Tables)

12 Months Ended

Dec. 31, 2022

Revenue from Contract with Customer [Abstract]

Disaggregation of Revenue

The following table summarizes our Total revenues:

						Year Ended December 31, 2022																								Year Ended December 31, 2021																								Year Ended December 31, 2020
(in millions)						U.S.						Europe						Other International						Total						U.S.						Europe						Other International						Total						U.S.						Europe						Other International						Total
Product sales:
HIV
Biktarvy						8,510						1,103						777						10,390						7,049						969						606						8,624						6,095						735						429						7,259
Complera/Eviplera						74						113						13						200						102						142						14						258						89						159						21						269
Descovy						1,631						118						123						1,872						1,397						164						139						1,700						1,526						197						138						1,861
Genvoya						1,983						284						136						2,404						2,267						391						221						2,879						2,605						490						243						3,338
Odefsey						1,058						364						47						1,469						1,076						440						52						1,568						1,172						450						50						1,672
Stribild						88						29						10						127						132						43						14						189						125						54						17						196
Truvada						113						15						18						147						314						22						35						371						1,376						27						45						1,448
Revenue share - Symtuza(1)						348						168						14						530						355						165						11						531						331						149						8						488
Other HIV(2)						15						24						17						57						136						30						29						195						332						26						49						407
Total HIV						13,820						2,219						1,155						17,194						12,828						2,366						1,121						16,315						13,651						2,287						1,000						16,938
Veklury						1,575						702						1,628						3,905						3,640						1,095						830						5,565						2,026						607						178						2,811
Hepatitis C virus (“HCV”)
Ledipasvir/ Sofosbuvir(3)						46						17						51						115						84						31						97						212						92						29						151						272
Sofosbuvir/Velpatasvir(4)						844						355						331						1,530						815						316						331						1,462						864						337						398						1,599
Other HCV(5)						115						40						10						166						119						74						14						207						132						48						13						193
Total HCV						1,005						413						392						1,810						1,018						421						442						1,881						1,088						414						562						2,064
Hepatitis B virus (“HBV”) / Hepatitis Delta virus (“HDV”)
Vemlidy						429						35						379						842						384						34						396						814						356						29						272						657
Viread						6						23						62						91						11						28						72						111						14						34						137						185
Other HBV/HDV(6)						—						55						—						55						2						42						—						44						10						8						—						18
Total HBV/HDV						435						112						441						988						397						104						468						969						380						71						409						860
Cell therapy
Tecartus						221						75						3						299						136						40						—						176						34						10						—						44
Yescarta						747						355						57						1,160						406						253						36						695						362						191						10						563
Total cell therapy						968						430						60						1,459						542						293						36						871						396						201						10						607
Trodelvy						525						143						12						680						370						10						—						380						49						—						—						49
Other
AmBisome						57						258						182						497						39						274						227						540						61						230						145						436
Letairis						196						—						—						196						206						—						—						206						314						—						—						314
Other(7)						135						65						53						253						136						115						30						281						176						84						16						276
Total Other						388						323						235						946						381						389						257						1,027						551						314						161						1,026
Total product sales						18,716						4,342						3,924						26,982						19,176						4,678						3,154						27,008						18,141						3,894						2,320						24,355
Royalty, contract and other revenues						168						127						4						299						91						196						10						297						76						241						17						334
Total revenues						$	18,884					$	4,469					$	3,928					$	27,281					$	19,267					$	4,874					$	3,164					$	27,305					$	18,217					$	4,135					$	2,337					$	24,689

_______________________________

(1)    Represents our revenue from cobicistat (“C”), emtricitabine (“FTC”) and tenofovir alafenamide (“TAF”) in Symtuza (darunavir/C/FTC/TAF), a fixed dose combination product commercialized by Janssen Sciences Ireland Unlimited Company (“Janssen”). See Note 10. Collaborations and Other Arrangements for additional information.

(2)    Includes Atripla, Emtriva, Sunlenca and Tybost.

(3)    Amounts consist of sales of Harvoni and the authorized generic version of Harvoni sold by our separate subsidiary, Asegua Therapeutics LLC.

(4)    Amounts consist of sales of Epclusa and the authorized generic version of Epclusa sold by our separate subsidiary, Asegua Therapeutics LLC.

(5)    Includes Vosevi and Sovaldi.

(6)    Includes Hepcludex and Hepsera.

(7)    Includes Cayston, Jyseleca, Ranexa and Zydelig.

Summarized Revenues from Major Customers

The following table summarizes revenues from each of our customers who individually accounted for 10% or more of our Total revenues:

						Year Ended December 31,
(as a percentage of total revenues)						2022						2021						2020
AmerisourceBergen Corporation						18		%				23		%				27		%
Cardinal Health, Inc.						25		%				22		%				21		%
McKesson Corporation						20		%				20		%				20		%

Revenues Recognized from Performance Obligations Satisfied in Prior Periods

The following table summarizes revenues recognized from performance obligations satisfied in prior periods:

						Year Ended December 31,
(in millions)						2022						2021						2020
Revenue share with Janssen(1) and royalties for licenses of intellectual property						$	783					$	851					$	841
Changes in estimates						$	582					$	856					$	101

_______________________________

(1)    See Note 10. Collaborations and Other Arrangements for additional information.

X

- Definition

Tabular disclosure of disaggregation of revenue into categories depicting how nature, amount, timing, and uncertainty of revenue and cash flows are affected by economic factor.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130545-203045

+ Details

Name:	us-gaap_DisaggregationOfRevenueTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- References

No definition available.

+ Details

Name:	us-gaap_RevenueFromContractWithCustomerAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of expected timing for satisfying remaining performance obligation.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 13
-Subparagraph (b)(1)
-URI https://asc.fasb.org/extlink&oid=126920106&loc=SL49130556-203045

+ Details

Name:	us-gaap_RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration

X

- Definition

Tabular disclosure of the extent of the entity's reliance on its major customers, if revenues from transactions with a single external customer amount to 10 percent or more of entity revenues, including the disclosure of that fact, the total amount of revenues from each such customer, and the identity of the reportable segment or segments reporting the revenues. The entity need not disclose the identity of a major customer or the amount of revenues that each segment reports from that customer. For these purposes, a group of companies known to the entity to be under common control is considered a single customer, and the federal government, a state government, a local government such as a county or municipality, or a foreign government is each considered a single customer.

+ References

No definition available.

+ Details

Name:	us-gaap_ScheduleOfRevenueByMajorCustomersByReportingSegmentsTableTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration